Literature DB >> 31896948

Report from the 20th annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; 28-29 September 2018.

D M Le1, S Ahmed2, S Ahmed2, B Brunet1, J Davies3, C Doll4, M Ferguson5, N Ginther6, V Gordon2, T Hamilton7, P Hebbard2, R Helewa8, C A Kim2, R Lee-Ying4, H Lim3, J M Loree3, J P McGhie9, K Mulder10, J Park2, D Renouf3, R P W Wong2, A Zaidi1, T Asif1.   

Abstract

The 20th annual Western Canadian Gastrointestinal Cancer Consensus Conference was held in Saskatoon, Saskatchewan, 28-29 September 2018. This interactive multidisciplinary conference is attended by health care professionals from across Western Canada (British Columbia, Alberta, Saskatchewan, and Manitoba) who are involved in the care of patients with gastrointestinal cancers. In addition, invited speakers from other provinces participate. Surgical, medical, and radiation oncologists, and allied health care professionals participated in presentations and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses current issues in the management of colorectal cancers. 2019 Multimed Inc.

Entities:  

Keywords:  Colorectal cancer; adjuvant radiation therapy; biomarkers; cytoreductive surgery; hipec; local excision; molecular tests; rectal cancer; sidedness; surgery; surveillance; total neoadjuvant treatment

Mesh:

Substances:

Year:  2019        PMID: 31896948      PMCID: PMC6927778          DOI: 10.3747/co.26.5517

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  76 in total

1.  Preoperative versus postoperative chemoradiotherapy for rectal cancer.

Authors:  Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab
Journal:  N Engl J Med       Date:  2004-10-21       Impact factor: 91.245

2.  The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials.

Authors:  Julian Walter Holch; Ingrid Ricard; Sebastian Stintzing; Dominik Paul Modest; Volker Heinemann
Journal:  Eur J Cancer       Date:  2016-11-29       Impact factor: 9.162

3.  Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis.

Authors:  Jan Franko; Zuhaib Ibrahim; Niraj J Gusani; Matthew P Holtzman; David L Bartlett; Herbert J Zeh
Journal:  Cancer       Date:  2010-08-15       Impact factor: 6.860

4.  Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging.

Authors:  G Brown; A G Radcliffe; R G Newcombe; N S Dallimore; M W Bourne; G T Williams
Journal:  Br J Surg       Date:  2003-03       Impact factor: 6.939

5.  Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients.

Authors:  Myrddin Rees; Paris P Tekkis; Fenella K S Welsh; Thomas O'Rourke; Timothy G John
Journal:  Ann Surg       Date:  2008-01       Impact factor: 12.969

Review 6.  Neoadjuvant Treatment Strategies for Locally Advanced Rectal Cancer.

Authors:  S Gollins; D Sebag-Montefiore
Journal:  Clin Oncol (R Coll Radiol)       Date:  2015-11-29       Impact factor: 4.126

7.  Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study.

Authors:  Dominique Elias; François Gilly; Florent Boutitie; François Quenet; Jean-Marc Bereder; Baudouin Mansvelt; Gérard Lorimier; Pierre Dubè; Olivier Glehen
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

8.  FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.

Authors:  F Loupakis; C Cremolini; L Salvatore; G Masi; E Sensi; M Schirripa; A Michelucci; E Pfanner; I Brunetti; C Lupi; C Antoniotti; F Bergamo; S Lonardi; V Zagonel; P Simi; G Fontanini; A Falcone
Journal:  Eur J Cancer       Date:  2013-10-15       Impact factor: 9.162

9.  An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer.

Authors:  Melanie Poulin-Costello; Laurent Azoulay; Eric Van Cutsem; Marc Peeters; Salvatore Siena; Michael Wolf
Journal:  Target Oncol       Date:  2013-04-27       Impact factor: 4.493

Review 10.  Recent developments in the treatment of metastatic colorectal cancer.

Authors:  Jonathan M Loree; Scott Kopetz
Journal:  Ther Adv Med Oncol       Date:  2017-06-29       Impact factor: 8.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.